.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,713,086

« Back to Dashboard

Claims for Patent: 6,713,086

Title: Controlled release formulation of divalproex sodium
Abstract:A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Inventor(s): Qiu; Yihong (Gumee, IL), Bollinger; J. Daniel (Libertyville, IL), Cheskin; Howard S. (Glencoe, IL), Dutta; Sandeep (Waukegan, IL), Engh; Kevin R. (Kenosha, IL), Poska; Richard P. (Mundelein, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/215,142
Patent Claims: 1. A oral polymeric controlled release formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium; b) a pharmaceutically acceptable hydrophilic polymer in which said hydrophilic polymer is present in the quantity of from about 20% to about 50%, by weight of the formulation, and said hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl celllose, methyl cellulose, vinyl acetate copolymers, polysaccharide, polyethylene oxide, methacrylic acid copolymers and maleic anhydride/methyl vinyl ether copolymers, and; c) when said formulation is ingested orally by healthy human subjects, said formulation produces a C.sub.max that is statistically significantly lower than the C.sub.max produced by an enteric coated delayed release divalproex sodium tablet given twice daily, when each is determined at steady state in a fasting population.

2. The formulation according to claim 1 which produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each is determined at steady state in a healthy fasting population.

3. The formulation according to claim 1 in which said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each is determined at steady state in a healthy fasting population.

4. The formulation according to claim 1 which: a) produces a C.sub.min in that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each is determined at steady state in a healthy fasting population, and; b) said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each is determined at steady state in a healthy fasting population.

5. The formulation according to claim 4 which produces a degree of fluctuation that is lower than the degree of fluctuation produced said delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population.

6. The formulation according to claim 1 in which said formulation is a matrix system, an osmotic pump system or a reservoir polymeric system.

7. A oral polymeric controlled release formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium b) a pharmaceutically acceptable hydrophilic polymer in which said hydrophilic polymer is present in the quantity of from bout 20% to about 50%, by weight of the formulation, and said hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethyl cellulose methyl cellulose, vinyl acetate copolymers, polysaccharides, polyethyleneoxide, methacrylic acid copolymers and maleic anhydride/methyl vinyl ether copolymers and; c) when said formulation is ingested orally by healthy human-subjects, said formulation produces: i. a C.sub.max that is statistically significantly lower than the C.sub.max produced by an enteric coated delayed release divalproex sodium tablet given twice daily, when each C.sub.max is determined at steady state in a fasting population, ii. a C.sub.min that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each C.sub.min is determined at steady state in a fasting population, and; iii. said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each AUC is determine at steady state in a fasting population.

8. The formulation according to claim 7 in which said formulation produces steady state peak plasma valproate levels that are about 10 to about 20% lower than that produced by a said delayed release divalproex sodium tablet.

9. A method for the treatment of migraine comprising the administration of a formulation according to claim 1 to a patient in need thereof.

10. A method for the treatment of epilepsy comprising the administration of a formulation according to claim 1 to a patient in need thereof.

11. A method for the reduction of side effects associated with divalproex sodium therapy comprising the administration of a formulation according to claim 1.

12. A oral polymeric controlled release formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium; b) a pharmaceutically acceptable hydrophilic polymer in which said hydrophilic polymer is present in the quantity of from about 20% to about 50%, by weight of the formulation, and said hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl celllose, methyl cellulose, vinyl acetate copolymers, polysaccharide, polyethylene oxide, methacrylic acid copolymers and maleic anhydride/methyl vinyl ether copolymers, and; c) when said formulation is ingested orally by healthy human subjects, said formulation produces a C.sub.max that is statistically significantly lower than the C.sub.max produced by an enteric coated delayed release divalproex sodium tablet given twice daily, when each is determined at steady state in a fasting population.

13. The formulation according to claim 3 which produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said twice daily dosage form when each is determined at steady state in a healthy fasting population.

14. The formulation according to claim 12 in which said formulation produces an AUC value that is equivalent to the AUC value generated by said bid valproate dosage form, when each is determined at steady state in a healthy fasting population.

15. The formulation according to claim 12 which: a) produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said bid valproate dosage form, when each is determined at steady state in a healthy fasting population, and; b) said formulation produces an AUC value that is equivalent to the AUC value generated by said bid valproate dosage form, when each is determined at steady state in a healthy fasting population.

16. The formulation according to claim 12 which produces a degree of fluctuation that is not statistically significantly different than the degree of fluctuation by produced the twice daily valproate dosage form, when each is determined at steady state in a fasting population.

17. The formulation according to claim 12 in which said formulation is a matrix system, an osmotic pump system or a reservoir polymeric system.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc